ELI LILLY & Co is 246.2x more valuable than Travere Therapeutics, Inc. by market capitalization ($1.070 T vs $4.35 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | TVTX | LLY |
|---|---|---|
| Market cap | $4.35 B | $1.070 T |
| US-listed rank | #1502 | #10 |
| Revenue (latest FY) | $490.73M | $65.18B |
| Net income (latest FY) | -$25.55M | $20.64B |
| Net margin | -5.2% | 31.7% |
| P/E (trailing FY) | - | 51.8 |
| SEC filings | 1,240 | 989 |
ELI LILLY & Co is 246.2x more valuable than Travere Therapeutics, Inc. by market capitalization ($1.070 T vs $4.35 B).
In their latest fiscal years, Travere Therapeutics, Inc. reported $490.73M in revenue while ELI LILLY & Co reported $65.18B.
Full pages: Travere Therapeutics, Inc. and ELI LILLY & Co, or browse the full rankings.